3K3A-Activated Protein C

3K3A-Activated Protein C is a modified form of the protein C molecule, which is a naturally occurring anticoagulant in the human body. It is designed to reduce the risk of bleeding complications associated with the use of tissue plasminogen activator (tPA), a drug used to treat ischemic stroke.

Mechanism of Action

3K3A-Activated Protein C works by reducing the activity of plasmin, an enzyme that breaks down blood clots. This action reduces the risk of bleeding complications associated with tPA treatment. It also has neuroprotective effects, which may help to reduce the damage caused by a stroke.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of 3K3A-Activated Protein C. These trials have shown promising results, with the drug demonstrating a good safety profile and potential benefits in terms of reducing stroke-related damage and improving patient outcomes.

Potential Applications

In addition to its potential use in the treatment of ischemic stroke, 3K3A-Activated Protein C may also have applications in other conditions associated with an increased risk of bleeding, such as traumatic brain injury and hemorrhagic stroke.

See Also

• Protein C
• Ischemic Stroke
• Hemorrhagic Stroke
• Clinical Trials
• Anticoagulant
• Neuroprotection

References

‎